Munich Reinsurance Co Stock Corp in Munich Purchases Shares of 61,962 Hologic, Inc. $HOLX

Key Points

• Munich Re bought a new stake of 61,962 Hologic shares in Q3, worth about $4.18 million, and institutional investors now own roughly 94.73% of the stock.
• Hologic reported quarterly results with EPS of $1.04 versus the $1.09 consensus and revenue of $1.05 billion (vs. $1.07 billion), with revenue up 2.5% year‑over‑year.
• Analysts mostly rate the stock a Hold (2 Buys, 13 Holds) with a consensus price target of $78.42; Hologic has a $16.91 billion market cap and a 52‑week range of $51.90–$75.75.

Munich Reinsurance Co Stock Corp in Munich purchased a new stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 61,962 shares of the medical equipment provider's stock, valued at approximately $4,182,000.

Other large investors have also modified their holdings of the company. Winnow Wealth LLC bought a new position in Hologic in the 3rd quarter worth $26,000. Root Financial Partners LLC bought a new stake in Hologic during the third quarter valued at about $27,000. SJS Investment Consulting Inc. grew its position in shares of Hologic by 341.5% in the third quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider's stock valued at $32,000 after purchasing an additional 362 shares during the last quarter. Smartleaf Asset Management LLC grew its position in shares of Hologic by 168.5% in the third quarter. Smartleaf Asset Management LLC now owns 494 shares of the medical equipment provider's stock valued at $33,000 after purchasing an additional 310 shares during the last quarter. Finally, Loomis Sayles & Co. L P bought a new position in shares of Hologic in the second quarter worth about $33,000. 94.73% of the stock is owned by institutional investors.

Hologic Stock Down 0.0%

HOLX stock opened at $75.74 on Friday. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $75.75. The company has a market cap of $16.91 billion, a PE ratio of 31.56, a price-to-earnings-growth ratio of 2.25 and a beta of 0.73. The business's 50-day simple moving average is $75.04 and its 200 day simple moving average is $72.41. The company has a quick ratio of 3.32, a current ratio of 4.04 and a debt-to-equity ratio of 0.48.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.09 by ($0.05). Hologic had a net margin of 13.18% and a return on equity of 19.58%. The firm had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter in the prior year, the firm earned $0.87 earnings per share. The company's revenue was up 2.5% on a year-over-year basis. On average, research analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms recently weighed in on HOLX. Morgan Stanley increased their target price on Hologic from $69.00 to $76.00 and gave the company an "equal weight" rating in a research note on Tuesday, November 11th. Evercore downgraded Hologic from an "outperform" rating to an "in-line" rating and dropped their price target for the stock from $79.00 to $78.00 in a research report on Monday, January 5th. Weiss Ratings reiterated a "hold (c)" rating on shares of Hologic in a report on Wednesday, January 28th. BNP Paribas Exane cut Hologic from a "strong-buy" rating to a "hold" rating and set a $79.00 price objective for the company. in a research report on Friday, November 21st. Finally, Argus downgraded shares of Hologic from a "buy" rating to a "hold" rating in a research note on Monday, January 12th. Two analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $78.42.

About Hologic

Hologic, Inc NASDAQ: HOLX is a global medical technology company specializing in women's health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.